Specialty Fit: Where da Vinci Wins, Where Orthopedic Platforms Win, and Where the Answer Is Neither

The most expensive mistake in surgical robot procurement is buying the right robot for the wrong specialty — or, more precisely, buying a platform marketed to a specialty for which it offers no meaningful advantage over what your surgeons are already doing.

A mid-tier community hospital system made exactly this decision in the early 2020s when it invested in a da Vinci platform primarily to serve its orthopedic surgery program. The system was technically cleared for soft-tissue procedures relevant to the hospital. But the orthopedic surgeons — whose cases represented the volume that would drive utilization — had no compelling clinical reason to move to the robotic platform from arthroscopic and open techniques they had mastered. The robot served a handful of urologic and gynecologic cases but never reached the volume that justified the capital. The orthopedic team eventually adopted a purpose-built robotic platform — a separate capital investment — because the clinical evidence for orthopedic robotics is specific to orthopedic systems.

Specialty mismatch is a systems-procurement failure, not a surgical robotics failure. Here is the framework for avoiding it.

Platform Categories — Four Distinct Technology Families

Surgical robots are not interchangeable. Four distinct technology families address different clinical domains:

Soft-tissue robotic-assisted surgery (RAS): da Vinci (Intuitive), Hugo (Medtronic), Versius (CMR), Senhance (Asensus). These platforms use robotic arms to hold and manipulate laparoscopic instruments. They are primarily relevant for minimally invasive abdominal, pelvic, and thoracic surgery.

Orthopedic robotic arthroplasty: Mako (Stryker), CORI (Smith & Nephew), ROSA Knee (Zimmer Biomet). These platforms use robotics to guide bone cutting or implant positioning in joint replacement surgery. Their clinical evidence, regulatory clearances, and commercial economics are entirely separate from soft-tissue platforms.

Spine robotic navigation: ExcelsiusGPS (Globus Medical), ROSA Spine (Zimmer Biomet), Mazor X (Medtronic). These systems assist with pedicle screw placement and other spinal implant procedures. Distinct indication set, distinct technology, distinct economic model.

ENT and specialty platforms: Emerging platforms for head and neck, ear surgery, and flexible endoscopy. The Intuitive SP has received attention for transoral and transvaginal approaches in ENT and urology, but most narrow-specialty robotics remain early-market.

Comparing these categories in a single RFP as if they were alternatives to each other is a category error. Your procurement process should separate them unless your facility is genuinely comparing platforms within the same clinical domain.

Where Soft-Tissue RAS Platforms Compete

For soft-tissue robotic surgery, the clinical evidence base is deepest in four specialty areas:

Urology — radical prostatectomy

Robotic-assisted radical prostatectomy (RARP) is the procedure where the evidence for robotic surgery over open or laparoscopic approaches is strongest and most consistent. Published systematic reviews report comparable oncologic outcomes to open surgery with advantages in blood loss, transfusion rates, length of stay, and return to continence. Robotic prostatectomy now accounts for a majority of radical prostatectomies performed in the U.S.

This is Intuitive's home territory. The da Vinci platform has the deepest evidence base and the most trained surgeons for prostatectomy. Hugo and Versius have published early prostatectomy data from European centers; their U.S. clearances as of early 2026 do not yet cover prostatectomy specifically.

Gynecology — hysterectomy and myomectomy

Robotic hysterectomy has strong evidence for specific populations: high-BMI patients, those with significant adhesion risk, complex cases where laparoscopic approach is technically difficult. For straightforward laparoscopic hysterectomy in uncomplicated patients, the robotic advantage over standard laparoscopy is less clear and the cost differential is substantial.

The specialty-fit question in gynecology is not "robotic vs open" — it is "which cases should be robotic vs laparoscopic?" This case-selection discipline drives program economics more than the platform choice.

General surgery — cholecystectomy, colorectal, hernia

Cholecystectomy is the most common soft-tissue robotic procedure by volume globally and the first indication CMR Versius received in the U.S. The evidence for robotic cholecystectomy showing outcome superiority over laparoscopic cholecystectomy is limited — the laparoscopic approach is already safe, minimally invasive, and well-mastered. Robotic cholecystectomy is often a training vehicle or a case mix contributor rather than a clinical priority.

Robotic colorectal surgery (sigmoidectomy, right colectomy, low anterior resection) has a stronger evidence case, particularly for deep pelvic dissection where the robotic wristed instruments offer technical advantages over straight laparoscopic instruments.

Robotic hernia repair is growing in volume but the clinical superiority evidence remains mixed.

Thoracic surgery — VATS vs robotic

Robot-assisted thoracic surgery (RATS) for lobectomy and segmentectomy competes primarily with video-assisted thoracoscopic surgery (VATS). The technical advantage is real in complex cases; the evidence for routine lobectomy is not as clearly differentiated. Thoracic robotics is growing but remains a specialty investment for higher-volume programs.

Where Orthopedic Platforms Compete — A Separate Evaluation

Stryker Mako is the dominant robotic platform in total knee arthroplasty (TKA) and total hip arthroplasty (THA) in the U.S. The Mako system uses patient-specific CT-based planning and haptic boundary technology to guide bone cutting. Published RCT-level evidence supports improved implant positioning accuracy versus conventional technique.

The clinical and economic case for Mako is distinct from soft-tissue robotics:

• High upfront capital ($800K–$1.4M) but no significant per-procedure consumable added cost beyond standard implant pricing
• Mako ties implant economics to Stryker's implant portfolio — a strategic consideration for facilities that manage multi-vendor implant contracts
• Return on investment is driven by surgeon recruitment, volume capture, and length-of-stay reduction in orthopedic patients, not by procedure-level instrument economics

Smith & Nephew CORI competes with Mako in partial and total knee arthroplasty using a hand-held saw guide rather than a patient-cart architecture. Lower capital cost; no pre-operative CT required (uses intraoperative morphing). Gaining market share against Mako in facilities where the radiation dose of pre-op CT is a concern.

Zimmer Biomet ROSA Knee offers similar functionality to Mako for TKA.

If your primary robotics need is orthopedic, evaluate Mako, CORI, and ROSA independently of your soft-tissue platform evaluation. The two evaluations share almost no clinical, economic, or vendor-management overlap.

ENT and Specialty Robotics: The Emerging Tier

da Vinci SP for transoral and transvaginal approaches — ENT surgeons performing transoral robotic surgery (TORS) for oropharyngeal and hypopharyngeal procedures have found specific advantage in the SP's flexible arm architecture. The SP can access deep pharyngeal anatomy through the mouth that the multiport Xi cannot. If your ENT program is evaluating robotic TORS, SP is the relevant platform and its indication-specific evidence is separate from the multiport program.

Flexible endoscopic robotics — platforms for advanced endoscopic interventions (POEM, ESD) are a distinct category and early-stage in the U.S. Medtronic and others have endoscopic robotics programs; these require separate evaluation if your gastroenterology or advanced endoscopy program is the driver.

A Specialty-by-Specialty Match Matrix

The Hardest Procurement Question: Do We Need a Platform or a Program?

The specialty-fit framework leads to a harder institutional question that procurement teams often avoid: are you buying a robot, or are you building a program?

A single surgeon who wants to perform robotic prostatectomy is not a program. A program is a credentialing structure, a volume commitment, a training pipeline, an OR team trained to the platform, and a clinical champion who will recruit peers. Without all of these, a platform purchased for specialty fit will still underperform.

Before specifying which platform fits your service line, answer: who are the two to three clinical champions who will own this program? What is their current volume? What is their credentialing status on robotic platforms? If you cannot name those people with confidence, the specialty-fit question is secondary to the organizational readiness question.

Next in this series: Surgeon Training Curve and Proctoring — The 18-Month Onboarding Window